Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biosensor Test System Developed Using Magnetic Nanoparticles

By LabMedica International staff writers
Posted on 14 Feb 2016
A new biosensor test system based on magnetic nanoparticles has been developed and it is designed to provide highly accurate measurements of the concentration of protein molecules in various samples, including opaque solutions or strongly colored liquids.

The analysis is conducted using small test strips made of porous material with two test lines. More...
A droplet of the sample liquid is applied to one end of the strip and after a short period the result is shown as the activation of one or both lines. The test can be done quickly and does not need to be carried out by specially trained staff; tests can easily be performed next to a patient or even in field conditions.

Scientists at Moscow Institute of Physics and Technology (Russia) have developed a dry-reagent immunomagnetic (DRIM) biosensing platform for rapid high-precision quantitative analyses for in vitro diagnostics. The platform combines the advantages of immunochromatography with highly sensitive quantification of 200-nm magnetic nanoparticles (MP) from the entire volume of lateral flow membranes. At molecular level, the magnetic nanoparticles "link" with antibodies to the required protein and then they are placed on a porous plate close to the intended point of contact with the test solution.

The new system was tested by measuring 25 pg/mL of prostate-specific antigen in the blood as the "healthy" range is anything lower than 4 ng/mL. Prostate-specific antigen is one of the most commonly monitored markers in clinical examinations on men. The scientists used their own patented method magnetic particle quantification (MPQ) to precisely count magnetic nanoparticles by their nonlinear magnetization. Using this method, scientists are able to record anything above 60 zmol (zeptomole; i.e., a factor of 10-21) of nanoparticles in a linear range exceeding ten million times in about 30 minutes. These parameters have never been recorded at this level before. The method involves applying an alternating magnetic field to the nanoparticles at two frequencies and monitoring the induction response at combinatorial frequencies.

The combination of reliability, accessibility, and high accuracy and sensitivity of the new method means that it is likely to make a rapid transition from a laboratory prototype to mass production. The developers have not yet given a specific timeframe, but they emphasize that their test system can be used not only to diagnose diseases, but also for a number of other applications. The study was published online on December 21, 2015, in the journal Biosensors and Bioelectronics.

Related Links:

Moscow Institute of Physics and Technology 



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Automated Urinalysis Solution
UN-9000
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.